젠큐릭스

229000KOSDAQ

60.0 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment20.0 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 15.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genex develops molecular diagnostic products and services based on liquid biopsy technology, focusing on cancer prognosis and companion diagnostics. Its key products include the breast cancer prognosis test 'GenesWell BCT' and the lung cancer companion diagnostic test 'GenesWell ddEGFR Mutation Test'. The company is also advancing early cancer detection through liquid biopsy products and CTC technology research.

Number of Employees

75people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.74Industry Average 1.200.0Point

2.3x industry avg (risky)

ROE

-47.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

2.55Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -102.0% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
젠큐릭스, 유로스타3 과제 주관기관 선정…공기 중 가축 바이러스 자.....
젠큐릭스가 유로스타3 과제 주관기관으로 선정되어 분자진단 분야에서의 국제 협력 강화로 긍정적 영향 기대.
Positive
"싱가포르 진출 속도"…젠큐릭스·인비트로큐 '맞손'
젠큐릭스의 싱가포르 시장 진출 계획과 인비트로큐와의 파트너십으로 인해 긍정적인 성장 기대감이 높아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 1,911Won52-week high 5,87052-week low 1,400

1-month return6.0Point

1m +15.82% (strong rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral[첨부정정]주요사항보고서(전환사채권발행결정)2026-09-03
Neutral주요사항보고서(전환사채권발행결정)2026-09-03
Neutral합병등종료보고서(합병)2026-09-01
Neutral주식매수선택권부여에관한신고2026-08-25
Neutral주주총회소집공고2026-08-25